Cargando…

SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy

BACKGROUND: In patients with immune-mediated rheumatic diseases (RMD), the development of T-cell responses against SARS-CoV-2 may be impaired by either the immune disturbances associated with the disease, or by the effects of immunosuppressive therapies. We aimed at determining the magnitude of SARS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lledó, Ana, Retuerto, Miriam, Almendro-Vázquez, Patricia, Fernández-Ruiz, Mario, Galindo, María, Laguna-Goya, Rocío, Paz-Artal, Estela, Lalueza, Antonio, Aguado, José M., Pablos, José L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572149/ https://www.ncbi.nlm.nih.gov/pubmed/34775160 http://dx.doi.org/10.1016/j.semarthrit.2021.10.006

Ejemplares similares

Defending against SARS-CoV-2: The T cell perspective
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2023)

A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities
por: Retuerto, Miriam, et al.
Publicado: (2022)

Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

Discordance Between SARS-CoV-2–specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2021)

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2022)

Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2021)

Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination
por: Horndler, Lydia, et al.
Publicado: (2023)

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
por: Arroyo-Sánchez, Daniel, et al.
Publicado: (2021)

Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
por: San-Juan, Rafael, et al.
Publicado: (2022)

IL-6–based mortality risk model for hospitalized patients with COVID-19
por: Laguna-Goya, Rocio, et al.
Publicado: (2020)

IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

Inborn Error of STAT2-Dependent IFN-I Immunity in a Patient Presented with Hemophagocytic Lymphohistiocytosis and Multisystem Inflammatory Syndrome in Children
por: López-Nevado, Marta, et al.
Publicado: (2023)

Perforin gene variant A91V in young patients with severe COVID-19
por: Cabrera-Marante, Oscar, et al.
Publicado: (2020)

Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome
por: Pleguezuelo, Daniel E., et al.
Publicado: (2021)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation
por: Ochando, Jordi, et al.
Publicado: (2019)

COVID-19 in rheumatic disease patients on immunosuppressive agents
por: Sharmeen, Saika, et al.
Publicado: (2020)

Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients
por: González-Cuadrado, Cecilia, et al.
Publicado: (2023)

Is it safe to vaccinate rheumatic immunosuppressed patients? Yes, of course, but how?
por: Gillet, Pierre
Publicado: (2021)

Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study
por: López-Medrano, Francisco, et al.
Publicado: (2021)

Population genetic analysis of bi-allelic structural variants from low-coverage sequence data with an expectation-maximization algorithm
por: Lucas-Lledó, José Ignacio, et al.
Publicado: (2014)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Rheumatism, Cerebral Embolism, Paralysis, Recovery
por: King, A. F. A.
Publicado: (1874)

Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination
por: Esparcia-Pinedo, Laura, et al.
Publicado: (2022)

Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea
por: Lee, Sang Yeob, et al.
Publicado: (2011)

T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression
por: Gil-Etayo, Francisco Javier, et al.
Publicado: (2021)

Isolated IgA Anti-β2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome
por: Ruiz-García, Raquel, et al.
Publicado: (2014)

Complement as a Therapeutic Target in Systemic Autoimmune Diseases
por: Galindo-Izquierdo, María, et al.
Publicado: (2021)

Effective Natural Killer Cell Degranulation Is an Essential Key in COVID-19 Evolution
por: Garcinuño, Sara, et al.
Publicado: (2022)

Case of Hyperpyrexia in Acute Rheumatism: Cold Bath; Recovery
por: Sinclair, Robert
Publicado: (1882)

IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection
por: Villegas, Carolina, et al.
Publicado: (2020)

Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination
por: Barbhaiya, Medha, et al.
Publicado: (2022)

Immune Response Against SARS-CoV-2 Infection and Vaccination in a CD8α-Deficient Patient
por: Arroyo-Sánchez, Daniel, et al.
Publicado: (2023)

Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
por: San-Juan, Rafael, et al.
Publicado: (2020)

Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
por: Clemente Garulo, Daniel, et al.
Publicado: (2023)

Antibody-removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single-center experience
por: Lasa-Lázaro, María, et al.
Publicado: (2023)

Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease
por: Serrano, Manuel, et al.
Publicado: (2014)

Cytomegalovirus Pneumonia in Patients with Rheumatic Diseases After Immunosuppressive Therapy: A Single Center Study in China
por: Xue, Yu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gut77i9o7k7l583m33mod375tk